Edwards Lifesciences Corporation (EW) Stock Analysis — Fair Value, Risk & Moat Rating
NYQ · Healthcare · Medical Devices
Is Edwards Lifesciences Corporation a safe investment right now?
Edwards Lifesciences Corporation's Altman Z-Score of 11.1 places it in the safe zone. Our fair value estimate is $87.71 (Watch Zone). Moat rating: 3.1/5 stars.
Could Edwards Lifesciences Corporation go bankrupt? Altman Z-Score analysis
Z-Score of 11.1 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives EW's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.3596 | 1.2 | 0.43 |
| B · Retained Earnings / Total Assets | RE / TA | 1.0397 | 1.4 | 1.46 |
| C · EBIT / Total Assets | EBIT / TA | 0.0944 | 3.3 | 0.31 |
| D · Market Cap / Total Liabilities | MCap / TL | 14.0947 | 0.6 | 8.46 |
| E · Revenue / Total Assets | Rev / TA | 0.443 | 1.0 | 0.44 |
How has EW's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 14.16 | Safe |
| 2023 | 13.48 | Safe |
| 2024 | 12.16 | Safe |
| 2025 | 11.1 | Safe |
Source: Calculated from EW's latest 10-K filing on SEC EDGAR.
What is Edwards Lifesciences Corporation actually worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $2.29 | Proprietary blend of reported actuals + analyst consensus, weighted by α |
| Last Year EPS | $1.83 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $2.97 | 27 analysts consensus |
| Trailing P/E | 45.0x | Current market pricing |
| Fair P/E (β discount) | 38.3x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Accelerating | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $96.33 (27 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Edwards Lifesciences Corporation have a durable competitive advantage?
Moat rating: 3.1/5.
What makes up EW's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 4/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 2/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is EW's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 24.0% | — |
| 2023 | 19.2% | Declining |
| 2024 | 14.8% | Declining |
| 2025 | 11.8% | Declining |
Source: ROIC calculated from SEC EDGAR filings.
Is Edwards Lifesciences Corporation's dividend safe?
Edwards Lifesciences Corporation's key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $6.1B | $5.4B | $4.5B | Rising |
| Net Income | $1.1B | $4.2B | $1.5B | Declining |
| Free Cash Flow | $1.3B | $0.3B | $1.0B | Rising |
| Gross Margin | 78.0% | 79.5% | 83.8% | Declining |
Recent events that affect our EW analysis
EW earnings report scheduled
Upcoming report. Consensus EPS estimate: $0.73. Revenue estimate: $1.60B. Our current Fair Value: $87.71 — a significant beat or miss could shift this estimate.
EW analyst consensus: 73% bullish (22 of 30 analysts)
5 Strong Buy, 17 Buy, 8 Hold, 0 Sell, 0 Strong Sell. Consensus target: $96.33 (18.2% upside). Compare with our independent Fair Value: $87.71.
EW filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
EW missed EPS estimates by 6.3%
Reported EPS: $0.58 vs estimate $0.62. Our Fair Value of $87.71 may face downward pressure if the trend continues.
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
EW filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
EW missed EPS estimates by 12.8%
Reported EPS: $0.50 vs estimate $0.57. Our Fair Value of $87.71 may face downward pressure if the trend continues.
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
EW filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
EW beat EPS estimates by 7.6%
Reported EPS: $0.67 vs estimate $0.62. Earnings strength supports our Fair Value of $87.71 (7.6% above current price).
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
EW filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
EW beat EPS estimates by 7.5%
Reported EPS: $0.64 vs estimate $0.60. Earnings strength supports our Fair Value of $87.71 (7.6% above current price).
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
EW filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
EW beat EPS estimates by 6.4%
Reported EPS: $0.59 vs estimate $0.55. Earnings strength supports our Fair Value of $87.71 (7.6% above current price).
EW filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about Edwards Lifesciences Corporation
What is Edwards Lifesciences Corporation stock price today?
Edwards Lifesciences Corporation (EW) stock price is $81.53 as of the latest market close, traded on the NYSE exchange.
What does Edwards Lifesciences Corporation do?
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
What is Edwards Lifesciences Corporation market cap?
Edwards Lifesciences Corporation has a market capitalization of $47.35B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is EW in?
Edwards Lifesciences Corporation operates in the Healthcare sector, specifically within the Medical Devices industry. It trades on the NYSE under the ticker symbol EW.
Is EW stock overvalued or undervalued?
Based on our valuation model, Edwards Lifesciences Corporation trades 7.0% below our fair value estimate — potentially undervalued.
- FairValueLabs Fair Value: $87.71
- Current Price: $81.53
- Valuation Zone: Watch Zone
What is EW stock forecast and analyst target price?
Based on 27 Wall Street analysts, the consensus price target for Edwards Lifesciences Corporation is $96.33, implying upside of 18.2% from the current price.
- Analyst High Target: $110.00
- Analyst Low Target: $84.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Edwards Lifesciences Corporation revenue and earnings growing?
Here are the analyst consensus growth estimates for Edwards Lifesciences Corporation:
- Revenue growth (current year est.): 10.0%
- EPS growth (current year est.): 16.0%
- Revenue growth (next year est.): 9.9%
- EPS growth (next year est.): 11.8%
What are Edwards Lifesciences Corporation's key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $6.1B | Rising |
| Net Income | $1.1B | Declining |
| Free Cash Flow | $1.3B | Rising |
| Gross Margin | 78.0% | Declining |
What is EW's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 45.0x
- Forward P/E (next 12 months est.): 24.6x
- FairValueLabs Fair P/E: 38.3x
How volatile is EW stock?
Edwards Lifesciences Corporation has a beta of 0.94, meaning it is roughly in line with overall market volatility. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Edwards Lifesciences Corporation have?
Edwards Lifesciences Corporation's balance sheet shows:
- Total Cash: $4.23B
- Total Debt: $705.4M
- Net Cash Position: $3.52B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is Edwards Lifesciences Corporation's free cash flow?
Edwards Lifesciences Corporation generated $1.17B in trailing twelve-month free cash flow (from $1.60B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does Edwards Lifesciences Corporation pay a dividend?
Edwards Lifesciences Corporation does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.
Is Edwards Lifesciences Corporation at risk of going bankrupt?
Edwards Lifesciences Corporation's Altman Z-Score is 11.10, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Edwards Lifesciences Corporation have a durable competitive advantage?
Edwards Lifesciences Corporation scores 3.1/5 stars (Narrow moat) in our moat analysis:
- ROIC Stability: 4/5
- Gross Margin Trend: 2/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is EW's return on equity (ROE)?
Edwards Lifesciences Corporation's return on equity is 10.3%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy EW stock?
EW shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol EW
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is EW a value stock or speculative?
FairValueLabs classifies Edwards Lifesciences Corporation as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.
Who is the CEO of Edwards Lifesciences Corporation?
The current CEO of Edwards Lifesciences Corporation is Mr. Bernard J. Zovighian.
What is EW's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $1.81
- Forward EPS (next 12 months est.): $3.32
- Analyst consensus EPS (this year): $2.97
- Analyst consensus EPS (next year): $3.32
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
EW analysis methodology: How we calculate fair value, Z-Scores, and moat ratings